Interim data in osteogenesis imperfecta show safety remains acceptable, but efficacy thresholds for early stopping were not met
Interim data in osteogenesis imperfecta show safety remains acceptable, but efficacy thresholds for early stopping were not met
Clinical trial results underscore safety and diagnostic accuracy for radiopharmaceutical imaging; Clarity pursues regulatory filings and wider manufacturing …
New oral vaccine succeeds against multiple cholera strains offering promise for broad use in endemic regions
Funding boost fuels hopes for first disease-modifying treatment in a rare genetic disorder
The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
European regulatory reforms are accelerating approvals for novel rare disease treatments, attracting global investment and expanding patient access.
Record venture investment is driving new biotech companies in Australia to accelerate research, clinical development, and global partnerships.
Large funding rounds and strategic partnerships highlight a more focused investment environment, concentrating on companies with late stage …
A landmark multi-hundred million dollar collaboration between Takeda and BridGene Biosciences redefines biotech funding trends this week, joined …
Longstanding trend of mega-rounds continues as February sees billions channeled into companies advancing therapies for oncology, rare diseases, …
Already a subscriber? Log in